Shopping Cart
Remove All
Your shopping cart is currently empty
Concizumab (Synonyms: NN 7415, mAb 2021)
Catalog No. T77373 Copy Product Info
🥰Excellent
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia.
Concizumab
Copy Product Info🥰Excellent
Catalog No. T77373
Synonyms NN 7415, mAb 2021
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia.
Concizumab
Cas No. 1312299-39-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $589 | In Stock | In Stock | |
| 10 mg | $967 | - | In Stock | |
| 25 mg | $1,430 | - | In Stock | |
| 50 mg | $1,930 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:> 95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia. |
| In vitro | In a concentration-dependent manner, Concizumab increases the peak value of thrombin [1]. |
| In vivo | In cynomolgus monkeys, Concizumab (i.v./s.c.) blocked the interaction between TFPI and FXa active site [2]. |
| Synonyms | NN 7415, mAb 2021 |
| Reactivity | Human |
| Verified Activity | Immobilized Human TFPI Protein (Fc) at 2 μg/mL (30 μL/well) can bind Concizumab. The EC50 is 14.01 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TFPI |
| Molecular Weight | 145.76 kDa |
| Cas No. | 1312299-39-0 |
| Isotype | Human IgG4SP kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Concizumab | purchase Concizumab | Concizumab cost | order Concizumab | Concizumab in vivo | Concizumab in vitro | Concizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.